Phytoceuticals Heals Wounds Through An Easy To Use Spray

Phytoceuticals is developing technology for wound care management through a combination of natural oils delivered through an easy to use spray.  This is a new solution that is poised to become the standard of care in wound management because of effective speed, ease of use and cost savings.

Primary Wound Dressing, an innovative wound spray that has been approved in the EU as a medical device, is specially formulated from a proprietary combination of two plant‐derived oils, and is designed to be a simple, natural and effective first choice product for the treatment of acute and chronic wounds as it is effective in a broad range of wound states and wound types.

“It creates a moist wound environment and the oil layer prevents the secondary dressing from adhering to the wound. These are minimal requirements a modern wound product has to meet,” said Prof. Dr. Thomas Hunziker, M.D., University Hospital, Bern, Switzerland. “Further­more the dressing has an antimicrobial effect and promotes the regeneration of the epidermis. These effects clearly make it a modern and convincing wound product of your first choice.”

Seeking a cure from a disease and its associated symptoms is one of the basic needs of human beings. Traditionally, healing power was wielded using remedies of regional natural origin tailored to individual needs. Today, traditional medicine has developed into different fields. As there is no intellectual property involved, the competition next door is allowed to produce a similar product. Marketing has hence a regional touch and sales potential for the single company is limited. These companies are trapped in a vicious circle, as the generally limited income does not allow for risky innovation and expensive evidence-based product development processes.

Phytoceuticals, a OneMedForum NY 2011 presenting company,  develops or acquires intellectual property from natural product extracts, defines scientifically sound development protocols, manages product development and then seeks exit options for these developed medicines.

The comments are closed.